Inovio Pharmaceuticals, Inc.
A maker of DNA-based vaccines and medicines that teach the body's own cells to fight disease. The company designs synthetic DNA instructions and delivers them with its hand-held CELLECTRA device, whose brief electrical pulses open tiny pores in cells to target cancers and HPV-related conditions. Founded in 1983 as Biotechnologies & Experimental Research, it later operated as Genetronics and took its current name after acquiring the Norwegian gene-delivery firm Inovio in 2005.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Adage Capital Management, L.P. | 13G/APassive | 4% | 3.43M | Aug 12, 2026 |
| Robert Atchinson | 13G/APassive | 4% | 3.43M | Aug 12, 2026 |
| Phillip Gross | 13G/APassive | 4% | 3.43M | Aug 12, 2026 |
| RA Capital Management, L.P. | 13GPassive | 9.9% | 10.67M | Aug 7, 2026 |
| Peter Kolchinsky | 13GPassive | 9.9% | 10.67M | Aug 7, 2026 |
| Rajeev Shah | 13GPassive | 9.9% | 10.67M | Aug 7, 2026 |
| RA Capital Healthcare Fund, L.P. | 13GPassive | 9.9% | 10.67M | Aug 7, 2026 |
| FMR LLC | 13G/APassive | 10.3% | 8.45M | Aug 6, 2026 |
| Abigail P. Johnson | 13G/APassive | 10.3% | 8.45M | Aug 6, 2026 |
| Vanguard Capital Management | 13GPassive | 5.05% | 4.16M | Jul 31, 2026 |